SCHEMBL5528586

SCHEMBL5528586

O=C1Nc2cc(Br)c([N+](=O)[O-])cc2C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 6/20 0.56
BCHE P06276 1/20 0.56
CAPN9 O14815 1/20 0.53
CASP3 P42574 1/20 0.53
TGM2 P21980 6/20 0.46
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
PKM P14618 1/20 0.38
MAPK1 P28482 2/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
STAT6 P42226 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31103500 0.93 CAPN9 (0.53) CES1BCHECAPN9CASP3TGM2
SCHEMBL15712858 0.80 CAPN9 (0.53) CES1BCHECAPN9CASP3TGM2
SCHEMBL8872707 0.80 CES1 (0.62) CES1BCHECAPN9CASP3TGM2
SCHEMBL15712304 0.80 CAPN9 (0.53) CES1BCHECAPN9CASP3TGM2
SCHEMBL13564439 0.80 CAPN9 (0.53) CES1BCHECAPN9CASP3TGM2
SCHEMBL421305 0.79 CYP3A4 (0.50) ALDH1A1MAPTPKMMAPK1TP53
SCHEMBL4737998 0.78 CES1 (0.71) CES1BCHECAPN9CASP3TGM2
SCHEMBL3303844 0.78 CAPN9 (0.50) CES1BCHECAPN9CASP3TGM2
SCHEMBL8555748 0.73 ALDH1A1 (0.40) CES1BCHECAPN9CASP3ALDH1A1
SCHEMBL18256571 0.72 CES1 (0.71) CES1BCHETGM2ALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065671-A1 BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS MERCK SHARP & DOHME CORP. 2011-03-17 US disclosed
US-20070276025-A1 Indirubin-Type Compounds, Compositions, and Methods for Their Use MEIJER LAURENT 2007-11-29 US disclosed
EP-1686988-A1 INDIRUBIN-TYPE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THEIR USE THE ROCKEFELLER UNIVERSITY (US) 2006-08-09 EP disclosed
WO-2005041954-A1 INDIRUBIN-TYPE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THEIR USE THE ROCKEFELLER UNIVERSITY (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065671-A1 BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS GPR119, GPR39, GPR65 CES1 450/4885BCHE 4059/4885CAPN9 3019/4885
US-20070276025-A1 Indirubin-Type Compounds, Compositions, and Methods for Their Use CDK3, GSK3B, CDK7 CES1 1902/4885BCHE 271/4885CAPN9 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.